Picking Up the Pieces After Hwang
By Gretchen Vogel,
Science
| 04. 28. 2006
A year ago, it seemed so easy. In May 2005, Woo Suk Hwang and his colleagues told the world that they could make embryonic stem (ES) cells from cloned human embryos with an efficiency that astounded--and thrilled--their colleagues. In roughly one out of every 12 tries, the South Korean team reported, they could produce ES cell lines that were a genetic match to patients. Scientists hoped to use such cells to probe the genetic triggers of diseases such as diabetes and amyotrophic lateral sclerosis (ALS). Some dreamed of using them as the raw material for developing new tissues and cells that could treat previously incurable maladies.
A few months ago, those claims famously unraveled. It is now clear that Hwang's team does not have any ES cell lines created from patients. It is also clear that the group didn't fail for lack of trying: The team apparently used more than 2200 donated human oocytes in their experiments--more than five times the number they claimed in their papers (Science, 10 February, p. 754). The meltdown dashed the hopes of researchers and...
Related Articles
By Courtney Withers and Daryna Zadvirna, ABC News | 12.03.2025
Same-sex couples, single people, transgender and intersex West Australians will be able to access assisted reproductive technology (ART) and surrogacy, almost a decade after reforms were first promised.
The landmark legislation, which removes the requirement for people to demonstrate medical...
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...